https://www.selleckchem.com/products/cp-91149.html resulted in a stronger association with AD than having only one autoimmune disease. Previous studies have demonstrated that a soluble urokinase-type plasminogen activator receptor (suPAR) plays an essential function in leukocytes and endothelial homeostasis and, therefore, in the development of coronary heart disease (CHD) and periodontitis. The aim of this study was to analyze the impact of gingival health, periodontitis, and CHD on suPAR levels in plasma and saliva and to evaluate suPAR as a biomarker of periodontitis and CHD. Healthy controls (n=33), patients with periodontitis (n=31), CHD (n=29), and a combination of periodontitis + CHD (n=29) were enrolled in the present study. All patients were clinically and periodontally evaluated and regularly assessed for socioeconomic status, serum lipids, high-sensitivity C-reactive protein (hs-CRP), and for plasma and salivary suPAR levels. Patients with periodontitis (P<.001) and with periodontitis + CHD (P<.001) presented higher median plasma and salivary suPAR levels compared with CHD and healthy controls. Moreover, univariate regasma and saliva, respectively. In the neurocritical care unit (neuro-ICU), the impact of continuous EEG (cEEG) on therapeutic decisions and prognostication, including outcome prediction using the Status Epilepticus Severity Score (STESS), is poorly investigated. We studied to what extent cEEG contributes to treatment decisions, and how this relates to clinical outcome and the use of STESS in neurocritical care. We included patients admitted to the neuro-ICU or neurological step-down unit of a tertiary referral hospital between 05/2013 and 06/2015. Inclusion criteria were ≥20h of cEEG monitoring and age ≥15years. Exclusion criteria were primary epileptic and post-cardiac arrest encephalopathies. Ninety-eight patients met inclusion criteria, 80 of which had status epilepticus, including 14 with super-refractory status. Median length of cEEG mo